Literature DB >> 7833626

Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells.

F Bühling1, D Kunz, D Reinhold, A J Ulmer, M Ernst, H D Flad, S Ansorge.   

Abstract

The expression and functional role of dipeptidyl peptidase IV (DP IV, CD26, EC 3.4.14.5) was studied on human natural killer (NK) cells. Here we show that freshly isolated NK cells do express only low amounts of DP IV. However, after IL-2 stimulation of NK cells (70% purity) surface DP IV expression was significantly increased in a subpopulation (30%) of these cells. Specific DP IV inhibitors (Lys-[Z-(NO2)]-piperidide, Lys-[Z(NO2)]-thiazolidide) and polyclonal antibodies directed against the ectopeptidase suppressed DNA synthesis and cell cycle progression of NK cells. The natural cytotoxic activity of DP IV+ CD56+ cells was found unchanged in comparison to those of DP IV- CD56+ cells. DP IV inhibitors had no effect on the natural cytotoxicity of mononuclear cells. From these data we conclude that DP IV is involved in the regulation of proliferation of NK cells, whereas natural cytotoxicity seems to be regulated independently.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7833626

Source DB:  PubMed          Journal:  Nat Immun        ISSN: 1018-8916


  18 in total

1.  Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15.

Authors:  T Yamabe; K Takakura; K Sugie; Y Kitaoka; S Takeda; Y Okubo; K Teshigawara; J Yodoi; T Hori
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

Review 2.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

3.  Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells.

Authors:  D Reinhold; U Bank; F Bühling; U Lendeckel; J Faust; K Neubert; S Ansorge
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

4.  Multicolor cytoenzymatic evaluation of dipeptidyl peptidase IV (CD26) function in normal and neoplastic human T-lymphocyte populations.

Authors:  P Ruiz; N Zacharievich; M Shenkin
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

5.  Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.

Authors:  Franziska Stehle; Kristin Schulz; Corinna Fahldieck; Jana Kalich; Rudolf Lichtenfels; Dagmar Riemann; Barbara Seliger
Journal:  J Biol Chem       Date:  2013-04-26       Impact factor: 5.157

6.  Characterization and expression of monoclonal antibody-defined molecules on resting and activated bovine αβ, γδ T and NK cells.

Authors:  Kun Taek Park; Keun Seok Seo; Natasha A Godwin; Bernard J Van Wie; M Yavuz Gulbahar; Yong Ho Park; William C Davis
Journal:  Vet Immunol Immunopathol       Date:  2015-09-10       Impact factor: 2.046

Review 7.  Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?

Authors:  Aleksi Sedo; Jonathan S Duke-Cohan; Eva Balaziova; Liliana R Sedova
Journal:  Arthritis Res Ther       Date:  2005-10-26       Impact factor: 5.156

8.  Dipeptidyl Peptidase-4 Regulates Hematopoietic Stem Cell Activation in Response to Chronic Stress.

Authors:  Enbo Zhu; Lina Hu; Hongxian Wu; Limei Piao; Guangxian Zhao; Aiko Inoue; Weon Kim; Chenglin Yu; Wenhu Xu; Yasuko K Bando; Xiang Li; Yanna Lei; Chang-Ning Hao; Kyosuke Takeshita; Woo-Shik Kim; Kenji Okumura; Toyoaki Murohara; Masafumi Kuzuya; Xian Wu Cheng
Journal:  J Am Heart Assoc       Date:  2017-07-14       Impact factor: 5.501

Review 9.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

Review 10.  Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease.

Authors:  Sebastian Steven; Thomas Münzel; Andreas Daiber
Journal:  Int J Mol Sci       Date:  2015-08-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.